X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs FULFORD INDIA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD FULFORD INDIA BIOCON LTD/
FULFORD INDIA
 
P/E (TTM) x 36.6 398.8 9.2% View Chart
P/BV x 4.9 6.2 78.2% View Chart
Dividend Yield % 1.5 0.1 1,796.7%  

Financials

 BIOCON LTD   FULFORD INDIA
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
FULFORD INDIA
Mar-14
BIOCON LTD/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs496942 52.6%   
Low Rs397450 88.1%   
Sales per share (Unadj.) Rs174.3691.4 25.2%  
Earnings per share (Unadj.) Rs44.811.5 390.9%  
Cash flow per share (Unadj.) Rs56.915.4 370.6%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %1.10.3 390.0%  
Book value per share (Unadj.) Rs202.8380.0 53.4%  
Shares outstanding (eoy) m200.003.90 5,128.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.0 254.3%   
Avg P/E ratio x10.060.7 16.4%  
P/CF ratio (eoy) x7.845.3 17.3%  
Price / Book Value ratio x2.21.8 120.1%  
Dividend payout %11.217.4 64.0%   
Avg Mkt Cap Rs m89,2202,714 3,286.9%   
No. of employees `0004.40.4 994.4%   
Total wages/salary Rs m6,363505 1,260.0%   
Avg. sales/employee Rs Th7,894.56,073.0 130.0%   
Avg. wages/employee Rs Th1,441.21,137.4 126.7%   
Avg. net profit/employee Rs Th2,029.7100.7 2,016.0%   
INCOME DATA
Net Sales Rs m34,8542,696 1,292.6%  
Other income Rs m845125 673.8%   
Total revenues Rs m35,6992,822 1,265.1%   
Gross profit Rs m8,200-46 -17,672.4%  
Depreciation Rs m2,42315 15,940.8%   
Interest Rs m10210 1,073.7%   
Profit before tax Rs m6,52054 12,007.4%   
Minority Interest Rs m-7440-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,7540-   
Tax Rs m2,56910 26,760.4%   
Profit after tax Rs m8,96145 20,047.0%  
Gross profit margin %23.5-1.7 -1,367.2%  
Effective tax rate %39.417.7 222.9%   
Net profit margin %25.71.7 1,550.9%  
BALANCE SHEET DATA
Current assets Rs m39,9321,738 2,297.2%   
Current liabilities Rs m16,276545 2,988.1%   
Net working cap to sales %67.944.3 153.3%  
Current ratio x2.53.2 76.9%  
Inventory Days Days5448 110.5%  
Debtors Days Days864 2,001.9%  
Net fixed assets Rs m39,10112 328,579.8%   
Share capital Rs m1,00039 2,564.1%   
"Free" reserves Rs m38,5911,443 2,674.4%   
Net worth Rs m40,5561,482 2,736.6%   
Long term debt Rs m20,7240-   
Total assets Rs m84,8162,077 4,084.2%  
Interest coverage x64.96.7 966.7%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.41.3 31.6%   
Return on assets %10.72.6 409.4%  
Return on equity %22.13.0 732.6%  
Return on capital %19.04.3 440.9%  
Exports to sales %30.70-   
Imports to sales %20.424.5 83.4%   
Exports (fob) Rs m10,717NA-   
Imports (cif) Rs m7,105659 1,077.7%   
Fx inflow Rs m11,78917 68,540.7%   
Fx outflow Rs m8,393673 1,246.8%   
Net fx Rs m3,396-656 -517.7%   
CASH FLOW
From Operations Rs m5,26490 5,848.9%  
From Investments Rs m-9,540105 -9,120.5%  
From Financial Activity Rs m10,867-14 -77,070.9%  
Net Cashflow Rs m6,591181 3,651.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 3.8 221.1%  
FIIs % 10.7 0.1 10,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.2 93.9%  
Shareholders   109,995 4,783 2,299.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - VENUS REMEDIES COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS